|
Published by: Drug and Market Development Publishing
Published: Jul. 1, 2006 - 312 Pages
Table of Contents
- Chapter 1: Executive Summary
- Introduction
- Current Status of Pain Therapeutics
- Current Status of Pain Therapeutics
- Pain Therapy Market Dynamics
- Conclusions
- Chapter 2: Introduction
- Scope and Nature of the Report
- Format of the Report
- Chapter 3: History of Pain Therapeutics
- References
- Chapter 4: Current Status of Pain Therapeutics
- The Nature of Pain
- The Neurophysiology of Pain
- Pain Pharmacology Today
- NSAIDs
- Narcotic Analgesics
- Non-Narcotic Analgesics,.Including Anti-Migraine Drugs
- Local Anesthetics
- Neuropathic Pain Drugs
- Non-Pharmacological Pain Therapy
- Pain Assessment
- Current Pain Management
- Post-Surgical Pain
- Neuropathic Pain
- Cancer Pain
- HIV/AIDS Pain
- Headache Pain
- Cluster Headaches
- Migraine Headaches
- Tension Headache
- Back Pain
- Arthritis Pain
- Psychogenic Pain
- Chapter 5: Current Pain Research and Development
- Basic Research Concepts and Tools
- Pain Research Methodologies
- Animal and Human Models
- In Vitro Methods
- Genomic Methods
- Pain Targets and Compounds
- Ion Channel Targets
- Sodium Channels
- Glutaminergic Channels
- Vanilloid Channels
- Cholinergic Channels
- Other Channels
- GPCR Targets
- Opioid Receptors
- Cannabinoid Receptors
- Other GPCR Receptors
- Development of Medications Addressing Other Mechanisms
- COX-2 Inhibition
- Nitric Oxide Synthase Modulators
- Therapeutic Antibodies and Peptides
- Miscellaneous or Anonymous Mechanisms
- References
- Chapter 6: Pain Therapy Market Dynamics
- General Observations
- Strategic Alliances
- Pain Drug R&D Survey
- Chapter 7: Company Profiles
- Abbott Laboratories
- Acadia Pharmaceuticals
- Adolor Corporation
- AstraZeneca
- CeNeS Pharmaceuticals plc
- Cognetix, Inc
- Corgentech Inc
- GlaxoSmithKline
- GW Pharmaceuticals
- Johnson & Johnson
- Merck & Co., Inc
- NeurogesX, Inc
- Neuromed Pharmaceuticals Inc
- NeuroTargets Ltd
- Novartis
- PainCeptor Pharma Corp
- Pain Therapeutics, Inc
- Pfizer, Inc
- Pharmos Corporation
- Renovis, Inc
- Rinat Neuroscience Corp
- Synt:em
- Vernalis
- VistaGen Therapeutics, Inc
- Xenome Ltd
- References
- Chapter 8: Interviews with Industry Experts
- Franz Hefti, Ph D., Executive Vice President, Drug Development, Rinat Neuroscience
- Jeffrey S. Mogil, Ph D., E P. Taylor Professor of Pain Studies; Canada Research Chair in Genetics of Pain; Dept. of Psychology and Centre for Research on Pain; McGill University
- Corey S. Goodman, Ph D., President, CEO, and Director, Renovis
- Remi Barbier, President, CEO, Chairman, Pain Therapeutics, Inc
- Neil Kurtz, M D., President and CEO of TorreyPines Therapeutics
- Chapter 9: Concluding Comments
- Table Of Exhibits
- Exhibit 4.1. Categories of Pain
- Exhibit 4.2. The Four Processes of Nociception
- Exhibit 4.3. Categorization of Analgesics
- Exhibit 4.4. Selected NSAIDs Containing Carboxyl Functionality
- Exhibit 4.5. Selected NSAIDs Containing Enolic and Phenolic Functionality
- Exhibit 4.6. Selected Opioids Categorized by Mode of Action
- Exhibit 4.7. Selected Opioids Categorized by Therapeutic Effect
- Exhibit 4.8. Descriptive Pain Scale
- Exhibit 4.9. Numeric and Analog Pain Scales
- Exhibit 4.10.. Hospital Medical Procedures for the Years 1994 and 2003 (in thousands)
- Exhibit 4.11. The World Health Organization Three-Step Analgesic Ladder
- Exhibit 4.12.. Estimates of Utilization of Increasingly Invasive Therapies in the Alleviation of. Cancer Pain
- Exhibit 4.13.. Key Issues in AIDS Pain Assessment
- Exhibit 4.14.. Characteristics of Major Headache Types
- Exhibit 4.15. Characteristics of Major Low Back Pain Types
- Exhibit 5.1. A Typical Neuron
- Exhibit 5.2. Interconnected Neurons
- Exhibit 5.3. A Neuronal Synapse
- Exhibit 5.4. A Generic Representation of Ion Channels
- Exhibit 5.5. A Nicotinic Acetylcholine Ligand-gated Ion Channel
- Exhibit 5.6. Examples of Ligand-Gated Ion Channels
- Exhibit 5.7. Receptors Coupled Through G-Proteins or Other Indirect Means
- Exhibit 5.8. Sodium Channel Modulators in Development
- Exhibit 5.9. Glutaminergic Channel Modulators in Development
- Exhibit 5.10. TRPV Vanilloid Channel Modulators in Development
- Exhibit 5.11. Cholinergic Channel Agonists in Development
- Exhibit 5.12. Other Ion Channel Modulators in Development
- Exhibit 5.13. Pharmacological Actions Corresponding to Opioid Receptors
- Exhibit 5.14. Opioid Receptor Modulators in Development
- Exhibit 5.15 Cannabinoid Receptor Modulators in Development
- Exhibit 5.16. Miscellaneous GPCR Modulators in Development
- Exhibit 5.17. COX-2 Inhibitors in Development
- Exhibit 5.18. Nitric Oxide Synthase Modulators in Development
- Exhibit 5.19. Therapeutic Antibodies and Peptides in Development
- Exhibit 5.20. Compounds with Other.(or Not Designated).Mechanisms in Development
- Exhibit 6.1. Recent Deal Activity in Pain Therapeutics
- Exhibit 6.2. Organization Type of Survey Respondents
- Exhibit 6.3.. Position Designations for Survey Respondents,.by Company Type
- Exhibit 6.4. Predominant Training Modality for Respondents
- Exhibit 6.5. Target Focus for Those in Basic Research or Early Discovery
- Exhibit 6.6. Drug Target Family Focus
- Exhibit 6.7. Have Newer Methods of Target Discovery Generated a.Pain Target?
- Exhibit 6.8. Therapeutic Indications for Compounds in Discovery or Development
- Exhibit 6.9. Level of Satisfaction with Neuropathic Pain Animal Models
- Exhibit 6.10. Degree of Confidence That One or More Drugs Highly Effective for Neuropathic. Pain Will Enter the Market in Five Years
- Exhibit 6.11. Pain Drug Discovery Budget Projections
- Exhibit 7.1. GlaxoSmithKline Pain Drug Pipeline, February 2006
- Exhibit 7.2. Merck Pain Drug Pipeline,.February 2006
AbstractD&MD’s new Pain Therapeutics market analysis report focuses on new advances in drug discovery and development. The report provides a background on pain, current therapies and research and development in the area. Profiles of companies with major pain programs include Abbott Laboratories, AstraZeneca, GlaxoSmithKline, GW Pharmaceuticals, Johnson & Johnson, Merck & Co., Neuromed Pharmaceuticals, Novartis, Pfizer, Vernalis, VistaGen Therapeutics, Xenome and more. In-depth interviews with industry leaders provide specific case studies from both biotech and academia that give a sense of what’s really going on in the trenches.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|
